The One Big Beautiful Bill Act, signed into law by President Donald Trump, has polarized opinions in the healthcare community due to its sweeping changes. Central to the apprehension is its significant reduction in Medicaid spending and the eradication of Affordable Care Act subsidies. These
Amid growing health crises and increasing global competition in pharmaceuticals, a novel FDA initiative aims to fast-track drug reviews by slashing approval times for essential medicines. Can this new approach significantly impact domestic drug manufacturing, or does it introduce unprecedented
In a decisive leap toward revolutionizing gene therapy, ProBio has unveiled its cutting-edge facility in Hopewell, New Jersey. This facility is poised to become a key player in the production of high-quality plasmid, lentiviral, and adeno-associated viral vectors tailored for genomic medicine. With
As the biopharmaceutical sector traverses the complex terrain of 2025, it encounters a multitude of challenges shaped by financial constraints, regulatory shifts, and evolving geopolitical dynamics. The industry is marked by notable changes detailed in Ernst & Young LLP's (EY) annual Biotech Beyond
Veranova has announced a major expansion of its Devens, Massachusetts facility, marking a significant step forward in the development and manufacturing of Antibody-Drug Conjugates (ADCs) and highly potent compounds. The company is investing $50 million to extend the facility by 9,000 square feet,
The biopharmaceutical industry finds itself at a crossroads as the ever-increasing global demand for pharmaceuticals necessitates a reevaluation of traditional manufacturing approaches. With escalating costs and inefficiencies hindering timely drug production, the sector is turning towards a
